Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29055666 | 0.82 | MAPT (0.41) | MAPTKDM4EGSK3BTGM2IDH1 | |
| SCHEMBL12727796 | 0.81 | PGR (0.50) | PGRPARP1MAPTKDM4EGAA | |
| SCHEMBL29087578 | 0.73 | PARP1 (0.39) | PARP1MAPTKDM4EGSK3BTGM2 | |
| SCHEMBL29087582 | 0.73 | IDH1 (0.41) | PARP1GSK3BTGM2IDH1PARP11 | |
| SCHEMBL10696421 | 0.73 | MAOA (0.50) | PGRMAPTL3MBTL1TGM2MAOB | |
| SCHEMBL29087587 | 0.73 | KDM4E (0.41) | PARP1MAPTKDM4EGSK3BTGM2 | |
| SCHEMBL30088920 | 0.73 | BRPF1 (0.53) | PGRPARP1MAPTKDM4EGAA | |
| SCHEMBL260994 | 0.73 | BRPF1 (0.53) | PGRPARP1MAPTKDM4EGAA | |
| SCHEMBL19054962 | 0.73 | BRPF1 (0.53) | PGRPARP1MAPTKDM4EGAA | |
| SCHEMBL7003692 | 0.72 | PARP1 (0.74) | PARP1GSK3BMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4845281-A | Method of preparing ketoprofen | BLASCHIM, S.P.A. (IT) | 1989-07-04 | — | — | US | claimed |
| EP-0309009-A1 | Process for preparing ketoprofen | Nobel Chemicals AB (SE) | 1989-03-29 | — | — | EP | claimed |
| US-9321775-B2 | Compositions and methods for the treatment of moderate to severe pain | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-9321775-B2 | Compositions and methods for the treatment of moderate to severe pain | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-20150148306-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | KANDULA MAHESH (IN) | 2015-05-28 | — | — | US | disclosed |
| US-20150141479-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141479-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-21 | — | — | US | disclosed |
| CN-1253543-A | Process for producing ketoprofen and 5-benzoyl-3-methyl-2-indolinone | MEDICAL INFORMATION SERVICES I (JP) | 2000-05-17 | — | — | CN | disclosed |
| EP-0990637-A1 | PROCESS FOR PRODUCING KETOPROFEN AND 5-BENZOYL-3-METHYL-2-INDOLINONE | Medical Information Services, Inc. (JP) | 2000-04-05 | — | — | EP | disclosed |
| US-4845281-A | Method of preparing ketoprofen | BLASCHIM, S.P.A. (IT) | 1989-07-04 | — | — | US | disclosed |
| US-4845281-A | Method of preparing ketoprofen | BLASCHIM, S.P.A. (IT) | 1989-07-04 | — | — | US | disclosed |
| EP-0309009-A1 | Process for preparing ketoprofen | Nobel Chemicals AB (SE) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148306-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | IAPP, TTR, GPR119 | PGR 1945/4885PARP1 2113/4885MAPT 265/4885 |
| US-20150141479-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN | TARDBP, GLS2, CACNA1S | PGR 2408/4885PARP1 3153/4885MAPT 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.